AFP and hepatocellular carcinoma: In that phase II trial, the effects of the TGFβ inhibitor LY2157299 in HCC patients with high alpha-fetoprotein (AFP) levels, which correlate with high TGFβ 1 levels, who failed Sorafenib treatment or were ineligible to receive Sorafenib were reported [584].